Seeking Harbour

Why Harbour BioMed acquired mAb licensing play Harbour Antibodies

The scarcity value of the bispecific HCab transgenic mouse technology developed by Harbour Antibodies B.V. - coupled with an established network of partners and licensing revenue - were the drivers behind new Chinese immuno-oncology play Harbour BioMed’s acquisition of the mAb platform company.

On

Read the full 437 word article

User Sign In